Published ECCO Guidelines
The aims of this Guidelines update is to review the evidence on the impact of IBD in sexuality, as well the impact of disease activity and treatment on fertility; to discuss the optimal management of IBD patients with a pregnancy wish, including counselling on disease risk on the offspring, the efficacy of reproductive medicine; to discuss the impact of pregnancy on IBD and the impact of IBD on pregnancy; to review the optimal management of IBD during pregnancy, including management of infectious diseases during pregnancy and the prevention of thromboembolism; to review the evidence on the effect of exposure to IBD drugs in utero on offspring, including the safety and efficacy of vaccines, and risk of infections; to discuss the optimal mode of delivery in patients with IBD; and to discuss disease management in the post-partum period, including the optimal time for re-starting medications, the safety of drugs during lactation.
The UC Treatment Consensus Guidelines 2019-2022 will be the second project to utilise the GRADE methodology. The first pioneer project to successfully use GRADE methodology was the GRADE CD Treatment Consensus Guideline 2017-2019. In this second GRADE project, the Clinical Treatment Guidelines part of the UC Guideline 2017 will be merged with the ECCO Evidence Based Consensus on Surgery for UC. It is not viable to cover surgical aspects with the GRADE methodology, hence these will still be covered utilising the Oxford Evidence Levels.
The last guideline on opportunisitic infection in IBD patients was published in 2014. The aims of the new guideline are the update the current and new biological therapies and their impact on opportunistic infections to summarise what to recommend to and IBD patient before, during and after travelling.
Children and adolescents with Crohn's disease (CD) often present a more complicated disease course compared to adult patients. In addition, the potential impact of CD on growth, pubertal and emotional development in patients underlines the need for a specific management strategy of paediatric CD. In 2014 the first consensus guidelines of ECCO/ESPGHAN were published in the Journal of Crohn’s and Colitis. Since then, new relevant therapeutic trials have been published that justify to update the guidelines. The aim is to provide detailed evidence-based recommendations and practice points for the treatment of children with CD.
These are the first ECCO Guidelines to adopt the GRADE approach [Grading of Recommendations Assessment, Development, and Evaluation] in order to provide transparent, high-quality, evidence-based recommendations on medical treatment in CD. The surgical treatment manuscript utilised the traditional Oxford Levels of Evidence in order to address surgical management, including preoperative aspects and drug management before surgery.
This new diagnostic consensus guideline is a joint project of the European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR] that now merges the former ECCO-ESGAR Imaging Guideline and the former ECCO Endoscopy Guideline, also including laboratory parameters. It has been drafted by 30 ECCO and ESGAR members from 17 European countries.
This is the second Nurses European Crohn’s and Colitis Organisation [N-ECCO] Consensus Statements document addressing inflammatory bowel disease [IBD] nursing across Europe. N-ECCO continues to be an active member of the European Crohn’s and Colitis Organisation [ECCO], providing education and networking opportunities for nurses across Europe within three designated nursing sessions, N-ECCO Network Meeting, N-ECCO School and the N-ECCO Research Forum, in addition to e-learning and podcasts.